Author

Dapo Ilo 1

1 AbbVie Inc., North Chicago, United States

BENEFIT–RISK ASSESSMENT OF UPADACITINIB TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Remo Panaccione, Irina Blumenstein, Peter Irving, Ramona Vladea, Dapo Ilo, Wen Zhou, Gweneth Levy, Xuan Yao, Iris Dotan

BENEFITS OF HIGH VERSUS LOW DOSE UPADACITINIB AS MAINTENANCE TREATMENT IN ULCERATIVE COLITIS PATIENTS WHO WERE RESPONDERS TO 8-WEEK INDUCTION WITH UPADACITINIB: RESULTS FROM THE U-ACHIEVE PHASE 3 MAINTENANCE TRIAL

Brian G. Feagan, Gareth Parkes, Pascal Juillerat, Krisztina Barbara Gecse, Xuan Yao, Wen Zhou, Huiwen Deng, Dapo Ilo, Yuri Sanchez Gonzalez, Peter D.R. Higgins

EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING 16 WEEKS’ EXTENDED INDUCTION TREATMENT FOLLOWED BY 52 WEEKS’ MAINTENANCE TREATMENT IN THE U-ACHIEVE/U-ACCOMPLISH TRIALS

Remo Panaccione, Silvio Danese, Wen Zhou, Justin Klaff, Dapo Ilo, Xuan Yao, Gweneth Levy, Peter D.R. Higgins, Edward V. Loftus Jr., Severine Vermeire

EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: FINAL RESULTS FROM THE PHASE 3 U-ACHIEVE MAINTENANCE STUDY

Severine Vermeire, Silvio Danese, Wen Zhou, Xuan Yao, Dapo Ilo, G Levy, Xavier Hebuterne, James O. Lindsay, Yuri Sanchez Gonzalez, Peter D.R. Higgins, Jean-Frédéric Colombel, Remo Panaccione

EFFICACY OF UPADACITINIB DOSE ESCALATION IN A PHASE 3 LONG-TERM EXTENSION ULCERATIVE COLITIS STUDY

Remo Panaccione, Millie Long, Zhihua Ran, Raja Atreya, Hiroshi Nakase, Wen Zhou, Xuan Yao, Dapo Ilo, Geert R. D'Haens

IMPACT OF INFLAMMATORY BURDEN ON EFFICACY OF UPADACITINIB MAINTENANCE THERAPY IN ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 U-ACHIEVE STUDY

Brian G. Feagan, Jean-Frédéric Colombel, Joana Torres, Toshimitsu Fujii, Wen Zhou, Xuan Yao, Yuri Sanchez Gonzalez, Dapo Ilo, Xavier Roblin

IMPACT OF INFLAMMATORY BURDEN ON EFFICACY OF UPADACITINIB MAINTENANCE THERAPY IN ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 U-ACHIEVE STUDY

Brian G. Feagan, Jean-Frédéric Colombel, Joana Torres, Toshimitsu Fujii, Wen Zhou, Xuan Yao, Yuri Sanchez Gonzalez, Dapo Ilo, Xavier Roblin

MATCHING-ADJUSTED INDIRECT COMPARISONOF UPADACITINIB VERSUS VEDOLIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Walter Reinisch, Severine Vermeire, Charlotte Hedin, David T. Rubin, Julian Panés, Huiwen Deng, Si Xuan, Lani Wegrzyn, John Liu, Dapo Ilo, Wen Zhou, Yuri Sanchez Gonzalez, Remo Panaccione

PATIENTS WITH ULCERATIVE COLITIS REPORT IMPROVEMENTS IN ABDOMINAL PAIN, BOWEL URGENCY, AND FATIGUE WITH 8-WEEK UPADACITINIB TREATMENT IN TWO PHASE 3 TRIALS: U-ACHIEVE AND U-ACCOMPLISH

Silvia Danese, Geert R. D'Haens, David T. Rubin, Remo Panaccione, Wen Zhou, Dapo Ilo, Michael Weinreich, Xuan Yao, Yuri Sanchez Gonzalez, William J. Sandborn

RAPIDITY OF SYMPTOM CONTROL WITH UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM TWO RANDOMIZED PHASE 3 STUDIES

Edward V. Loftus, Ken Takeuchi, Xiang Gao, Remo Panaccione, Dapo Ilo, Tricia Finney-Hayward, Wen Zhou, Silvio Danese, Charles Phillips, Xuan Yao, Severine Vermeire

Item 1 - 10 / 12
1
2